Spectrum Pharmaceuticals (SPPI) Stock Price, News & Analysis

Company Overview

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $1.03 to $1.03
• 50-Day Range: $0.94 to $1.03
• 52-Week Range: $0.32 to $1.57
• Volume: N/A
• Average Volume: 1.93 million shs
• Market Capitalization: $211.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Spectrum Pharmaceuticals Stock Analysis - MarketRank™

Spectrum Pharmaceuticals scored higher than 10% of companies evaluated by MarketBeat, and ranked 882nd out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Spectrum Pharmaceuticals.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Spectrum Pharmaceuticals are expected to grow in the coming year, from ($0.14) to $0.07 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Spectrum Pharmaceuticals is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Spectrum Pharmaceuticals is -2.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Spectrum Pharmaceuticals has a P/B Ratio of 6.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for SPPI.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Spectrum Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Spectrum Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.75

Short Interest

There is no current short interest data available for SPPI.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

2 people have searched for SPPI on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Spectrum Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.70% of the stock of Spectrum Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 21.67% of the stock of Spectrum Pharmaceuticals is held by institutions.

SPPI Stock Analysis - Frequently Asked Questions

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) posted its earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.07.
Read the conference call transcript.

What other stocks do shareholders of Spectrum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Spectrum Pharmaceuticals investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Globant (GLOB), Toast (TOST), Ginkgo Bioworks (DNA) and NOVONIX (NVNXF).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 7/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SPPI
• CIK: 831547
• Web: www.sppirx.com
• Phone: (617) 586-3900
• Fax: 702-260-7405
• Employees: 86
• Year Founded: 2002

Profitability

• EPS (Trailing Twelve Months): ($0.36)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$75.40 million
• Net Margins: N/A
• Pretax Margin: -263.04%
• Return on Equity: -218.44%
• Return on Assets: -66.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.71
• Quick Ratio: 2.38

Sales & Book Value

• Annual Sales: $10.11 million
• Price / Sales: 20.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.15 per share
• Price / Book: 6.87

Miscellaneous

• Outstanding Shares: 205,250,000
• Free Float: 199,704,000
• Market Cap: $211.41 million
• Optionable: Optionable
• Beta: 2.15